RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2023

Sep 7, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2023-09-05

Reporting Person: Lee Jennifer Kayden (EVP, Head of North America)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-09-05	Common Stock	M	4519	$6.80	Acquired	7813	Direct
2023-09-05	Common Stock	S	6166	$28.0502	Disposed	1647	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-09-05	Stock Option (Right to Buy)	$6.80	M	4519	Disposed	2032-02-08	Common Stock (4519)	Direct

Footnotes

F1: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2023.

F2: The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $28.00 to $28.25. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

F3: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.